If you watch television, you've probably come across a commercial for AndroGel, AbbVie's (NYSE:ABBV) blockbuster prescription gel for treating low testosterone levels. The technical term for the ailment is hypogonadism, and it's a $2 billion market -- and growing. Markets like that don't come without admirers, and in this case one of those is Repros Therapeutics (NASDAQ:RPRX). The company is developing an oral drug for secondary hypogonadism called Androxal, and in the following video Brenton Flynn discusses why its stock soared today.
Motley Fool Returns
Stock Advisor S&P 500
5 Years 57% 38%
17+ years 350% 95%
Stock Advisor launched in February of 2002. Returns as of 12/08/2019.Join Stock Advisor